http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
Zai Lab (ZLAB), Novocure (NVCR) Announce China NMPA Approves Optune for Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
Novocure Reports First Quarter 2020 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at AACR
-
Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virt
-
Novocure (NVCR) Announces Business Update Related to COVID-19
-
Novocure Provides Business Update Related to COVID-19
-
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany
-
Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System
-
Novocure (NVCR) Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy
-
Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy
-
Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces National Reimbursement in Israel for Optune in Combination with Temozolomide for Treatment of Newly Diagnosed Glioblastoma
-
Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
-
Novocure (NVCR) Reports Prelim. Q4 & FY19 Net Revenues Above Consensus; Provides Company Update
-
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
-
Zai Lab Limited (ZLAB), Novocure (NVCR) Report First Patient Enrolled in Ph. 2 Pilot Trial of Tumor Treating Fields with Chemotherapy
-
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
-
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
-
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
-
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
-
SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
-
SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
-
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
-
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
-
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
-
Novocure (NVCR) Reports Publication of Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma
-
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
-
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
-
Novocure to Report Third Quarter 2019 Financial Results
-
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
-
Zai Lab (ZLAB) and Novocure (NVCR) Announces China NMPA Granted Innovative Medical Device Designation for Optune
-
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
-
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
-
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
-
Novocure to Participate in Three Upcoming Investor Conferences
-
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
-
Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference
-
CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®
-
Novocure to Report Second Quarter 2019 Financial Results
-
Novocure (NVCR) Announces German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune's Survival Benefit for Patients with Newly Diagnosed GBM
-
German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma
-
Novocure to Participate in the Jefferies 2019 Global Healthcare Conference
-
Novocure (NVCR) Announces FDA Approves NovoTTF-100LTM System in Combination with Chemotherapy for Treatment of MPM
-
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
-
Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
-
Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastom
